Ad hoc: MorphoSys to Start Share Buy-Back Program

2013-04-22T18:10:19 CET

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today the decision to repurchase its own shares on the stock market. Following approval by the Company's Supervisory Board, the Board of Management of MorphoSys AG has resolved to acquire up to 85,000 MorphoSys shares over the stock market during the time period from April 22, 2013 to May 10, 2013. On the basis of the current share price (status: April 19, 2013), this would amount to around EUR 2.6 million or up to 0.36% of the share capital.

The Company intends to use the shares for its long-term incentive programs for its management, but the shares can also be used for all purposes stated in the authorization of the Annual General Meeting of May 19, 2011.

The buy-back is to be handled independently of and uninfluenced by the Company through an appointed bank in compliance with the safe-harbor provisions.

END OF AD HOC ANNOUNCEMENT

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

 

 

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com